Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ATI-1777

Small molecule · developed by Aclaris Therapeutics

Phase 2 Most advanced trial (none active)

ACRS Developer

2 Registered trials

What is ATI-1777?

ATI-1777 is an investigational small-molecule drug studied in Atopic Dermatitis.

At a glance

Drug type: Small molecule
Therapy area: Dermatology
Developer: Aclaris Therapeutics, Inc. (ACRS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: DQN3V3R84U

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05432596	Phase 2	Atopic Dermatitis	Completed	ACRS
NCT04598269	Phase 2	Atopic Dermatitis	Completed	ACRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atopic Dermatitis

More from Aclaris Therapeutics

A-101 FDA approved ATI 502 Phase 2 ATI-045 Phase 2 ATI-2138 Phase 2 ATI-50002 Phase 2 ATI-501 Phase 2 Zunsemetinib Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ACRS page.

Follow ACRS, the company behind ATI-1777

See ACRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACRS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z